Article
Author(s):
Chicago - The promise of biochemotherapy for stage IV malignant melanoma has not held up to scrutiny, and the value of this form of treatment seems nil, according to recent discouraging findings from major phase III clinical trials.
Exploring the Effects of Masks on Skin Physiology
The Cutaneous Connection: Intervening in AD Progression for Pediatric Patients
Clinical Pearls for Vitiligo and Pigmentation Complexities: Part 3
The Cutaneous Connection: Navigating Systemic Therapies in Atopic Dermatitis
Which Tax Treatment Is Best for Your Dermatology Practice?
Facing Challenges in Pediatric Plaque Psoriasis